首页> 外文学位 >Customizing intracranial nanoparticle distribution during convection-enhanced delivery: Application in the treatment of an intracranial tumor model with camptothecin-loaded PLGA nanoparticles.
【24h】

Customizing intracranial nanoparticle distribution during convection-enhanced delivery: Application in the treatment of an intracranial tumor model with camptothecin-loaded PLGA nanoparticles.

机译:自定义对流增强输送过程中颅内纳米颗粒的分布:应用载有喜树碱的PLGA纳米颗粒治疗颅内肿瘤模型的应用。

获取原文
获取原文并翻译 | 示例

摘要

Despite advances in medical imaging, the survival rate for patients with Glioblastoma Multiforme (GBM), the most prevalent variety of primary brain tumor, remains unchanged for the past two decades. GBM is difficult to treat because of its aggressive invasion into the surrounding tissue. Traditional chemotherapy is largely ineffective against GBM due to the blood-brain-barrier, which excludes many chemotherapy agents. Local polymeric drug delivery has had clinical success, but the efficacy is limited by low drug penetration via diffusional transport. Convection-enhanced delivery (CED) is a new clinical technology to increase intracranial drug distribution by inducing convective flow; it is hampered however, by unpredictable distribution of the infused drug.;The goal of this project was to design and evaluate a drug delivery strategy utilizing both controlled release technology via polymer nanoparticles and CED. Nanoparticle surface coatings and infusate solution properties were selected to improve intracranial distribution volume. Infusate solutions were selected to either dilate the extracellular matrix (ECM) of the brain, or to degrade selected components of the ECM. Each infusion strategy was designed to increase the extracellular volume fraction available for particle movement. The ECM dilation strategies, a saline pretreatment or a co-infusion with mannitol, increased distribution volume by 123% and 51%. Degrading the ECM with hyaluronidase increased nanoparticle distribution by 64%.;Nanoparticle surfaces were selected to either extend or restrict their distribution by taking advantage of ECM properties. A range of nanoparticle surfaces were evaluated in an intracranial model. Distribution could be extended as far as 2.2 mm3 by coating with bovine serum albumin (BSA), or restricted to 0.2 mm3 with the adhesion protein fibronectin (FN).;Biodegradable poly(lactic-co-glycolic acid) nanoparticles loaded with camptothecin and surface modified with either BSA or FN were used against an orthotopic glioma model using CED. The drug-loaded nanoparticles were effective against an experimental tumor; they increased median survival, and in 30% of the cases the animals survived until the end of the study and exhibited no residual tumor. The success in our intracranial model illustrates the utility of the combined approach to brain cancer chemotherapy, and invites the use of this easily translatable therapy.
机译:尽管医学成像技术取得了进步,但在过去的二十年中,多形性胶质母细胞瘤(GBM)患者(原发性脑瘤最普遍的患者)的存活率保持不变。 GBM难以治疗,因为它会侵入周围组织。由于血脑屏障,传统化学疗法对GBM很大程度上无效,这排除了许多化学疗法药物。局部聚合药物递送在临床上取得了成功,但是其功效受到药物通过扩散转运的低渗透性的限制。对流增强递送(CED)是一种新的临床技术,可通过诱导对流来增加颅内药物的分布。该项目的目标是利用通过聚合物纳米颗粒和CED的控释技术设计和评估药物输送策略。选择纳米颗粒表面涂层和输注溶液性能以改善颅内分布体积。选择输注溶液以扩张大脑的细胞外基质(ECM),或降解ECM的选定成分。设计每种输注策略以增加可用于颗粒运动的细胞外体积分数。 ECM扩张策略,盐水预处理或与甘露醇的共同输注使分配量增加了123%和51%。用透明质酸酶降解ECM可使纳米颗粒的分布增加64%。;通过利用ECM特性选择纳米颗粒表面以扩展或限制其分布。在颅内模型中评估了一系列纳米颗粒表面。用牛血清白蛋白(BSA)包被可扩展至2.2 mm3,或用粘附蛋白纤连蛋白(FN)限制为0.2 mm3。可生物降解的负载有喜树碱和表面的聚乳酸-乙醇酸纳米颗粒使用CED对BSA或FN修饰的原位神经胶质瘤模型进行治疗。载有药物的纳米粒子对实验性肿瘤有效。它们增加了中位存活率,在30%的情况下,动物存活到研究结束,并且没有残留肿瘤。我们颅内模型的成功说明了联合方法在脑癌化学疗法中的实用性,并邀请使用这种易于翻译的疗法。

著录项

  • 作者

    Sawyer, Andrew Jeffrey.;

  • 作者单位

    Yale University.;

  • 授予单位 Yale University.;
  • 学科 Engineering Biomedical.;Engineering Chemical.
  • 学位 Ph.D.
  • 年度 2009
  • 页码 150 p.
  • 总页数 150
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号